Pseudo-
allergic reactions-adverse, non-immunologic,
anaphylaxis-like sudden onset reactions mediated through an
IgE-independent pathway-are activated by various basic compounds and occur at least as frequently as
IgE-mediated reactions to drugs. A large family of
G protein coupled receptors (Mas-related genes; Mrgprs) is closely related to pseudo-
allergies. However, few
therapies can directly target pseudo-
allergies and related Mrgprs.
Saikosaponin A (SSA) is effective in the treatment of passive cutaneous anaphylaxis (PCA),
adjuvant arthritis, and delayed hypersensitiveness. In this study, we investigated the anti-pseudo-
allergy effect of SSA and its underlying mechanism. We examined the effect of SSA on both
IgE-independent and
IgE-dependent responses using PCA and active systemic
anaphylaxis models, as well as in vitro-cultured mast cells. We also evaluated whether the anti-
allergy effect is related to Mrgprs by using in vitro Mrgprx2-expressing HEK293 cells. SSA dose dependently suppressed
compound 48/80 (C48/80)-induced PCA and mast cell degranulation in mice. When SSA and C48/80 were administered together through the vein, C48/80-induced systemic
anaphylaxis did not occur, and C48/80-induced
shock ratio decreased dose-dependently upon SSA treatment. However, SSA did not affect
IgE-dependent
allergy. When administered topically 24 h before
antigen challenge,
Evans blue leakage and paw swelling were induced in the SSA-treated group and the vehicle group. Our in vitro studies revealed that SSA reduced C48/80-induced
calcium flux and suppressed degranulation in
LAD2 cells. SSA could also dose-dependently inhibit C48/80-induced Mrgprx2-expressing HEK293 cell activation. As a conclusion, SSA could inhibits
IgE-independent
allergy, but not
IgE-dependent
allergy, and this effect involves the Mrgprx2 pathway. This study provided a new sight on pseudo-
allergy and its
therapy.